Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women

References

• Planey SL, Kumar R, Arnott JA. Estrogen receptors (ERalpha versus ERbeta): friends or foes in human biology? J Recept Signal Transduct Res. 2014;34(1):1–5.
   PubMed Web of Science ®Google Scholar
• Johnson AB, O’Malley BW. Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol Cell Endocrinol. 2012;348(2):430–439.
   PubMed Web of Science ®Google Scholar
• Ma G, Ren Y, Wang K, et al. SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci. 2011;7(5):664–672.
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Wardell SE. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol. 2010;10(6):620–628.
   PubMed Web of Science ®Google Scholar
• Sporn MB, Dowsett SA, Mershon J, et al. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther. 2004;26(6):830–840.
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337(23):1641–1647.
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–645.
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Duvernoy CS, Calaf J, et al. Raloxifene use in clinical practice: efficacy and safety. Menopause. 2009;16(2):413–421.
   PubMed Web of Science ®Google Scholar
• Evista R. (raloxifene hydrochloride): package insert. Indianapolis (IN):Lilly; 1998. Available from: http://pi.lilly.com/us/evista-pi.pdf.
   Google Scholar
• Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol. 1999;85(1):23–29.
   PubMed Web of Science ®Google Scholar
• Heringa M. Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther. 2003;41(8):331–345.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Marcus C, Holmes F, et al. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology. 1988;45(5):344–345.
   PubMed Web of Science ®Google Scholar
• Gradishar W, Glusman J, Lu Y, et al. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer. 2000;88(9):2047–2053.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Bundred NJ, Decensi A, et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev. 2001;10(9):961–966.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90(18):1371–1388.
   PubMed Web of Science ®Google Scholar
• Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. The Lancet. 1998;352(9122):98–101.
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian tamoxifen prevention study. Lancet. 1998;352(9122):93–97.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817–824.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296–300.
   PubMed Web of Science ®Google Scholar
• Clemens JA, Bennett DR, Black LJ, et al. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 1983;32(25):2869–2875.
   PubMed Web of Science ®Google Scholar
• Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 1983;32:1031–1036.
   PubMed Web of Science ®Google Scholar
• Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93(1):63–69.
   PubMed Web of Science ®Google Scholar
• Fuchs-Young R, Glasebrook AL, Short LL, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci. 1995;761:355–360.
   PubMed Web of Science ®Google Scholar
• Sato M, Glasebrook AL, Bryant HU. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Met. 1994;12(Suppl S2):S9–S20.
   Google Scholar
• Baker VL, Draper M, Paul S, et al. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab. 1998;83(1):6–13.
   PubMed Web of Science ®Google Scholar
• Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11(6):835–842.
   PubMed Web of Science ®Google Scholar
• Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130(5):431–439.
   PubMed Web of Science ®Google Scholar
• Eng-Wong J, Reynolds JC, Venzon D, et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab. 2006;91(10):3941–3946.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. multiple outcomes of raloxifene evaluation. JAMA. 1999;281(23):2189–2197.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001;65(2):125–134.
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23):1751–1761.
   PubMedGoogle Scholar
• Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–137.
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (star) p-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696–706.
   PubMed Web of Science ®Google Scholar
• Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104(4):837–844.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20(1):47–63.
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117(12):1016–1037.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–613.
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49–57.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2013;310(13):1353–1368.
   PubMed Web of Science ®Google Scholar
• Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279(18):1445–1451.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287(7):847–857.
   PubMed Web of Science ®Google Scholar
• Wenger NK, Barrett-Connor E, Collins P, et al. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol. 2002;90(11):1204–1210.
   PubMed Web of Science ®Google Scholar
• Faupel-Badger JM, Prindiville SA, Venzon D, et al. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1153–1158.
   PubMed Web of Science ®Google Scholar
• Eng-Wong J, Orzano-Birgani J, Chow CK, et al. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1696–1701.
   PubMed Web of Science ®Google Scholar
• Serrano D, Lazzeroni M, Gandini S, et al. A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res. 2013;15(3):R47.
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–2741.
   PubMed Web of Science ®Google Scholar
• Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–1886.
   PubMed Web of Science ®Google Scholar
• Wickerham DL, Cecchini RS, Vogel VG, et al. Final updated results of teh NRG oncology/NSABP protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. J Clin Oncol. 2015;33(suppl 15):1500.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–1834.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. Ther Clin Risk Manag. 2009;5:817–827.
   PubMedGoogle Scholar
• Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686–696.
   PubMed Web of Science ®Google Scholar
• Lasofoxifene: UKMi new drugs online database; [Aug 1, 2016]. Available from: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=3184.
   Google Scholar
• FDA. Final summary minutes. Advisory committee for reproductive health drugs meeting. September 8, 2008. Available from http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4381m1-final.pdf. 2008. Accessed Aug 1, 2016.
   Google Scholar
• Pickar JH, MacNeil T, Ohleth K. SERMs: progress and future perspectives. Maturitas. 2010;67(2):129–138.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014;142:142–154.
   PubMed Web of Science ®Google Scholar
• EMA. European public assessment report (EPAR) for Conbriza. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000913/human_med_000723.jsp&mid=WC0b01ac058001d124
   Google Scholar
• FDA. FDA approves Duavee to treat hot flashes and prevent osteoporosis updated July 10, 2015; [ cited Aug 1, 2016]. Available from: http://www.fda.gov/Drugs/NewsEvents/ucm370679.htm.
   Google Scholar
• Mocellin S, Pilati P, Briarava M, et al. Breast cancer chemoprevention: a network meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2016;108:2.
   Google Scholar
• Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol. 2001;54(3):149–154.
   PubMedGoogle Scholar
• Hu X, Juneja SC, Maihle NJ, et al. Leptin–a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst. 2002;94(22):1704–1711.
   PubMedGoogle Scholar
• Laud K, Gourdou I, Pessemesse L, et al. Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol. 2002;188(1–2):219–226.
   PubMed Web of Science ®Google Scholar
• Marttunen MB, Andersson S, Hietanen P, et al. Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients. Maturitas. 2000;35(2):175–179.
   PubMed Web of Science ®Google Scholar
• Eng-Wong J, Hursting SD, Venzon D, et al. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1468–1473.
   PubMed Web of Science ®Google Scholar
• Signori C, DuBrock C, Richie JP, et al. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. Eur J Clin Nutr. 2012;66(8):878–884.
   PubMed Web of Science ®Google Scholar
• Lazzeroni M, DeCensi A. Alternate dosing schedules for cancer chemopreventive agents. Semin Oncol. 2016;43(1):116–122.
   PubMed Web of Science ®Google Scholar
• Dunn BK, Greene MH, Kelley JM, et al. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int J Mol Epidemiol Genet. 2010;1(4):332–349.
   PubMedGoogle Scholar
• Kolata G. Fearing drugs’ rare side effects, millions take their chances with osteoporosis. New York Times; 2016. Sect. Health section. [cited 2016 Jun 2]. Available from: http://www.nytimes.com/2016/06/02/health/osteoporosis-drugs-bones.html?_r=1
   Google Scholar
• National Institute for Health and Care Excellence (NICE) GUIDELINES [CG154]. NICE GUIDELINES [CG154] familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. https://www.nice.org.uk/guidance/CG164/chapter/1-Recommendations#risk-reduction-and-treatment-strategies.
   Google Scholar